Item 2.01  Completion of Acquisition or Disposition of Assets.
On April 15, 2020, Kindred Biosciences, Inc. (the "Company") issued a press
release announcing the completion on that day of its previously announced sale
of Mirataz® to Dechra Pharmaceuticals PLC. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated
herein by reference. As described in the press release, the Company received a
payment of $43 million and royalties on worldwide sales. As is customary, 10% of
the upfront payment is being held in escrow for up to 18 months post-closing.
Item 9.01  Financial Statements and Exhibits.
(d)  Exhibits
Exhibit No.    Description
   99.1          Press Release of Kindred Biosciences, Inc. issued on April 15,
               2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses